Resources

Industry execs foresee drug innovation and AI breakthroughs in 2026.

Multi-modal learning has significantly advanced generative AI, especially in vision-language modeling. Innovations like GPT-4V and open-source projects such as LLaVA have enabled robust conversational agents capable of zero-shot task completions.

Over the next three years, we will develop a versatile AI foundation model that integrates health records, medical images, and genomic data from the UK Biobank. Our goal is to set a new standard in predicting disease risk, forecasting outcomes, and uncovering biological drivers of both common conditions (like cancer) and rare disorders.

Proteomics data is essential to pathogenic understanding of a disease phenotype. In cancer, analysis of molecular signatures enables precision medicine through the identification of biological processes that drive individualized tumor progression, therapeutic resistance, and clinical heterogeneity.

Distinguishing the rare “driver” mutations that fuel cancer progression from the vast background of “passenger” mutations in the non-coding genome is a fundamental challenge in cancer biology.

Electronic Health Records (EHRs) contain rich temporal dynamics that conventional encoding approaches fail to adequately capture.